Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab
Marshall Journal of Medicine · 28.04.2023 · 9 (2)
DOI: 10.33470/2379-9536.1390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marshall Journal of Medicine, online erschienen am 28.04.2023. Verfasst von Jacob R Kilgore und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Eruptive lentigines in the area of resolving psoriatic plaques has been well documented in the literature following successful treatment with multiple therapies. This is historically associated with light treatment but has been expanded to include other therapies such as anti-tumor necrosis factor therapies and, more recently, some biologics5. Guselkumab (Tremfya) is an IgG1λ monoclonal antibody used in the treatment of plaque psoriasis with only one case of eruptive lentigines confined to resolving psoriatic plaques (ELRP) noted as a side effect. We present the second such case of ELRP associated with successful treatment of plaque psoriasis with Guselkumab, as it is important to document potential side effects of medications regardless of their severity.
Zitieren
APA
Kilgore, J. R., Curry, J. C., & Cook, S. E. (2023). Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab. Marshall Journal of Medicine, 9(2). https://doi.org/10.33470/2379-9536.1390
Vancouver
Kilgore JR, Curry JC, Cook SE. Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab. Marshall Journal of Medicine. 2023;9(2). doi:10.33470/2379-9536.1390
BibTeX
@article{Kilgore2023,
author = {Kilgore, Jacob R and Curry, James C and Cook, Shane E},
title = {Eruptive Lentigines Confined to Resolving Psoriatic Plaques Following Treatment with Guselkumab},
journal = {Marshall Journal of Medicine},
year = {2023},
volume = {9},
number = {2},
doi = {10.33470/2379-9536.1390}
}
EUVIMED